docosahexaenoic acid (RT011) / BioJiva - LARVOL DELTA

RPE dysfunction in Gpx4 KO mice with features of dry AMD is reversed by oral D-DHA: support for a phase I/II clinical trial (ARVO 2026) - P1/2 | "We previously reported that administration of deuterated docosahexaenoic acid (D-DHA) prior to KO protects the retina against development of AMD-like pathology (ARVO 2025)...Conclusions D-DHA administered after retinal insult in Gpx4ΔRPE mice halts photoreceptor/RPE degeneration and restores RPE function. These results support a newly initiated clinical trial aimed at preserving vision in AMD patients with extrafoveal geographic atrophy (Clinicaltrials.gov NCT07029945)."

P1/2 data • Preclinical • Age-related Macular Degeneration • Dry Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • GPX4

Orally administered deuterium-reinforced polyunsaturated fatty acids (D-PUFAs) with increased resistance against retinal lipid peroxidation (LPO) (ARVO 2025) - "Methods C57BL/6 mice were fed diets containing either bis-allylic deuterated linoleic acid (D2-LA), arachidonic acid (D6-AA) or docosahexaenoic acid (D10-DHA), or their non-deuterated counterparts...95, 11352 Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."

Diabetic Macular Edema • Diabetic Retinopathy • Ophthalmology • Retinal Disorders

Orally administered Deuterium-reinforced Docosahexaenoic Acid (D-DHA, BRX011) as a mutation-independent neuroprotective therapy for Autosomal Dominant Retinitis Pigmentosa (adRP) (ARVO 2025) - "We compared visual acuity (VA) and retinal function/structure in a humanized P23H RHO 'knock-in' adRP mouse model (hRHOP23H/+)2 fed D-DHA or H-DHA. Still, based on VA data, D-DHA may be a viable mutation-independent therapeutic candidate for adRP to maintain VA in RP patients.1Liu, Y. et al, 20222McCall M. et al, 2022 Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."

Age-related Macular Degeneration • Dry Age-related Macular Degeneration • Inherited Retinal Dystrophy • Ocular Inflammation • Ophthalmology • Retinal Disorders • Retinitis Pigmentosa • CDKN1A

Orally administered Deuterium-reinforced Docosahexaenoic Acid (D-DHA, BRX011), protects photoreceptors in a pig model of Autosomal Dominant Retinitis Pigmentosa (adRP) (ARVO 2025) - "Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."

Preclinical • Inherited Retinal Dystrophy • Ocular Inflammation • Ophthalmology • Retinal Disorders • Retinitis Pigmentosa • CDKN1A

Maternal dietary deuterated docosahexaenoic acid protects against hyperoxia induced retinal vascular arrest (ARVO 2024) - "Maternal dietary D-DHA protects against hyperoxia-induced retinal VA. Preservation of early normal vascular development is critical in preventing ROP. D-DHA also increased total DHA levels in serum and retina at P17, and attenuated redox markers."

Ophthalmology • Retinal Disorders • Retinopathy of Prematurity • SOD2